Table 3.
Summary of antibody-based DLL/Notch inhibitors in clinical development in oncology.
| Antibody | Target | Company | Clinical status | Reference |
|---|---|---|---|---|
| OMP52M51 (Brontictuzumab) | Notch1 | OncoMed (Acquired by Mereo BioPharma in 2019) | 1 | Ferrarotto et al (52) |
| OMP-59R5 (Tarextumab) | Notch2&3 | OncoMed | 2 | Hu et al (53), Smith et al (54) |
| SC16LD6.5, Rova-T (Rovalpituzumab Tesirine) | DLL3/ADC | AbbVie (Originally by Stemcentrx) | 3 | Morgensztern et al (55), Hann et al (56), Mansfield et al (57) |
| MEDI0639 | DLL4 | MedImmune | 1 | Falchook et al (58) |
| OMP21M18 (Demcizumab) | DLL4 | OncoMed | 2 | Coleman et al (59), McKeage et al (60), Smith et al (61) |
| REGN421 (Enoticumab) | DLL4 | Regeneron | 1 | Chiorean et al (62), Strickler et al (79) |
| AMG 757 | DLL3/CD3 bispecific antibody | Amgen | 2 | Giffin et al (63), Fu et al (78) |
| ABL001 (CTX-009/ES104/NOV1501/HD105) | DLL4/VEGF bispecific antibody | ABL Bio (Compass/Elpiscience/Handock) | 2 | Lee et al (64) |
| ABT-165 (Dilpacimab) | DLL4/VEGF bispecific antibody | AbbVie | 2 | Gordon et al (65), Strickler et al (79) |
| OMP-305B83 (Navicixizumab) | DLL4/VEGF bispecific antibody | OncoMed (OncXerna Therapeutics) | 3 | Jimeno et al (66), Fu et al (78) |